Literature DB >> 26827653

Alzheimer's disease-like pathology has transient effects on the brain and blood metabolome.

Xiaobei Pan1, Muhammad Bin Nasaruddin1, Christopher T Elliott1, Bernadette McGuinness2, Anthony P Passmore2, Patrick G Kehoe3, Christian Hölscher4, Paula L McClean5, Stewart F Graham6, Brian D Green7.   

Abstract

The pathogenesis of Alzheimer's disease (AD) is complex involving multiple contributing factors. The extent to which AD pathology affects the metabolome is still not understood nor is it known how disturbances change as the disease progresses. For the first time, we have profiled longitudinally (6, 8, 10, 12, and 18 months) both the brain and plasma metabolome of APPswe/PS1deltaE9 double transgenic and wild-type mice. A total of 187 metabolites were quantified using a targeted metabolomic methodology. Multivariate statistical analysis produced models that distinguished APPswe/PS1deltaE9 from wild-type mice at 8, 10, and 12 months. Metabolic pathway analysis found perturbed polyamine metabolism in both brain and blood plasma. There were other disturbances in essential amino acids, branched-chain amino acids, and also in the neurotransmitter serotonin. Pronounced imbalances in phospholipid and acylcarnitine homeostasis were evident in 2 age groups. AD-like pathology, therefore, affects greatly on both the brain and blood metabolomes, although there appears to be a clear temporal sequence whereby changes to brain metabolites precede those in blood.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  APP/PS1; Alzheimer's disease; Blood; Brain; Metabolites; Metabolomics

Mesh:

Substances:

Year:  2015        PMID: 26827653     DOI: 10.1016/j.neurobiolaging.2015.11.014

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  33 in total

1.  Skyline for Small Molecules: A Unifying Software Package for Quantitative Metabolomics.

Authors:  Kendra J Adams; Brian Pratt; Neelanjan Bose; Laura G Dubois; Lisa St John-Williams; Kevin M Perrott; Karina Ky; Pankaj Kapahi; Vagisha Sharma; Michael J MacCoss; M Arthur Moseley; Carol A Colton; Brendan X MacLean; Birgit Schilling; J Will Thompson
Journal:  J Proteome Res       Date:  2020-03-26       Impact factor: 4.466

2.  What success can teach us about failure: the plasma metabolome of older adults with superior memory and lessons for Alzheimer's disease.

Authors:  Mark Mapstone; Feng Lin; Mike A Nalls; Amrita K Cheema; Andrew B Singleton; Massimo S Fiandaca; Howard J Federoff
Journal:  Neurobiol Aging       Date:  2016-11-21       Impact factor: 4.673

3.  Reverting Metabolic Dysfunction in Cortex and Cerebellum of APP/PS1 Mice, a Model for Alzheimer's Disease by Pioglitazone, a Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Agonist.

Authors:  Kai Lun Chang; Ling Rong Wong; Hai Ning Pee; Shili Yang; Paul Chi-Lui Ho
Journal:  Mol Neurobiol       Date:  2019-04-23       Impact factor: 5.590

Review 4.  Molecular Probes, Chemosensors, and Nanosensors for Optical Detection of Biorelevant Molecules and Ions in Aqueous Media and Biofluids.

Authors:  Joana Krämer; Rui Kang; Laura M Grimm; Luisa De Cola; Pierre Picchetti; Frank Biedermann
Journal:  Chem Rev       Date:  2022-01-07       Impact factor: 60.622

5.  Targeted metabolomics highlights perturbed metabolism in the brain of autism spectrum disorder sufferers.

Authors:  Stewart F Graham; Onur Turkoglu; Ali Yilmaz; Ilyas Ustun; Zafer Ugur; Trent Bjorndhal; BeomSoo Han; Rupa Mandal; David Wishart; Ray O Bahado-Singh
Journal:  Metabolomics       Date:  2020-04-24       Impact factor: 4.290

6.  Aberrant AZIN2 and polyamine metabolism precipitates tau neuropathology.

Authors:  Leslie A Sandusky-Beltran; Andrii Kovalenko; Devon S Placides; Kevin Ratnasamy; Chao Ma; Jerry B Hunt; Huimin Liang; John Ivan T Calahatian; Camilla Michalski; Margaret Fahnestock; Laura J Blair; April L Darling; Jeremy D Baker; Sarah N Fontaine; Chad A Dickey; Joshua J Gamsby; Kevin R Nash; Erin Abner; Maj-Linda B Selenica; Daniel C Lee
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

7.  Likelihood ratio statistics for gene set enrichment in Alzheimer's disease pathways.

Authors:  Jordan Bryan; Arpita Mandan; Gauri Kamat; W Kirby Gottschalk; Alexandra Badea; Kendra J Adams; J Will Thompson; Carol A Colton; Sayan Mukherjee; Michael W Lutz
Journal:  Alzheimers Dement       Date:  2021-01-21       Impact factor: 21.566

8.  Metabolic network failures in Alzheimer's disease: A biochemical road map.

Authors:  Jon B Toledo; Matthias Arnold; Gabi Kastenmüller; Rui Chang; Rebecca A Baillie; Xianlin Han; Madhav Thambisetty; Jessica D Tenenbaum; Karsten Suhre; J Will Thompson; Lisa St John-Williams; Siamak MahmoudianDehkordi; Daniel M Rotroff; John R Jack; Alison Motsinger-Reif; Shannon L Risacher; Colette Blach; Joseph E Lucas; Tyler Massaro; Gregory Louie; Hongjie Zhu; Guido Dallmann; Kristaps Klavins; Therese Koal; Sungeun Kim; Kwangsik Nho; Li Shen; Ramon Casanova; Sudhir Varma; Cristina Legido-Quigley; M Arthur Moseley; Kuixi Zhu; Marc Y R Henrion; Sven J van der Lee; Amy C Harms; Ayse Demirkan; Thomas Hankemeier; Cornelia M van Duijn; John Q Trojanowski; Leslie M Shaw; Andrew J Saykin; Michael W Weiner; P Murali Doraiswamy; Rima Kaddurah-Daouk
Journal:  Alzheimers Dement       Date:  2017-03-22       Impact factor: 16.655

9.  Metabolic Profiling of Amino Acids Associated with Mortality in Patients with Acute Paraquat Poisoning.

Authors:  Xiuxian Wan; Chunyu Zhou; Xin Kang; Dayong Hu; Wen Xue; Xinhua Li; Hui Bao; Ai Peng
Journal:  Med Sci Monit       Date:  2018-03-07

Review 10.  Application of Metabolomics in Alzheimer's Disease.

Authors:  Jordan Maximillian Wilkins; Eugenia Trushina
Journal:  Front Neurol       Date:  2018-01-12       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.